MaxCyte, Inc. (MXCT)
- Previous Close
3.8800 - Open
3.8500 - Bid 3.9400 x 400
- Ask 3.9700 x 300
- Day's Range
3.8200 - 3.9700 - 52 Week Range
2.4500 - 5.5450 - Volume
534,108 - Avg. Volume
592,391 - Market Cap (intraday)
416.129M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.25
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
www.maxcyte.comRecent News: MXCT
Performance Overview: MXCT
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MXCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MXCT
Valuation Measures
Market Cap
405.87M
Enterprise Value
256.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.70
Price/Book (mrq)
1.74
Enterprise Value/Revenue
6.21
Enterprise Value/EBITDA
-5.81
Financial Highlights
Profitability and Income Statement
Profit Margin
-91.85%
Return on Assets (ttm)
-10.88%
Return on Equity (ttm)
-15.60%
Revenue (ttm)
41.29M
Net Income Avi to Common (ttm)
-37.92M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
168.29M
Total Debt/Equity (mrq)
8.07%
Levered Free Cash Flow (ttm)
-10.91M
Research Analysis: MXCT
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell